<DOC>
	<DOCNO>NCT01184976</DOCNO>
	<brief_summary>Research Hypothesis : VGX-3400 ( DNA plasmid encode hemagglutinin ( HA ) , neuraminidase ( NA ) , M2e-NP antigen H5N1 avian influenza virus ) administer healthy adult male IM injection follow EP generally well tolerate immunogenic .</brief_summary>
	<brief_title>Study Of VGX-3400 , H5N1 Avian Flu Virus Plasmid DNA With Electroporation Device In Healthy Adult Males</brief_title>
	<detailed_description />
	<criteria>Written inform consent accordance institutional guideline . If require local law , candidate must also authorize release use protect health information ( PHI ) Male subject 2039 year age Healthy subject judge Investigator base medical history , physical examination , normal result ECG , CBC , serum chemistry , CPK urinalysis do 30 day prior enrollment administration study drug Current nonsmoker Body mass index ( BMI ) ≤30 kg/m2 Able willing comply study procedure . Positive serological test HIV virus , hepatitis C virus hepatitis B virus surface antigen ( HBsAg ) ; Any concurrent condition require continue use systemic topical steroid ( exclude inhale eye dropcontaining corticosteroid ) ; use immunosuppressive immune modify agent within 3 month prior Day 0 corticosteroid ; systemic topical corticosteroid must discontinue &gt; 4 week prior Day 0 Administration blood product within 3 month enrollment Prior receipt H5N1 influenza vaccine time Administration nonstudy vaccine 6 week prior study enrollment Subject currently participate participate study investigational compound device within 30 day sign informed consent ; Metal implant site injection , however , metal implant elsewhere permit represent exclusion criterion ; Active substance abuse use drug heroin , cocaine drug addiction daily use alcohol great 100 ml whiskey liquor , great 300 ml wine , great 360 ml beer daily study period week prior start study ; Subjects whose deltoid quadriceps available ; Subjects receive antiviral drug &amp; primary thrombocytopenia ; Serious Adverse reaction vaccine include anaphylaxis relate symptom hive , respiratory difficulty , angioedema , and/or abdominal pain ( Not exclude : participant nonanaphylactic adverse reaction pertussis vaccine child ) ; Autoimmune disease , include GuillainBarré syndrome ; Clinically significant medical condition , physical exam finding , clinically significant abnormal laboratory result , past medical history clinically significant implication current health . A clinically significant condition process include limit : A process would affect immune response ; A process would require medication affect immune response ; Any contraindication repeat injection blood draw ; A condition require active medical intervention monitoring avert grave danger participant 's health wellbeing study period ; A condition process sign symptom could confuse reaction vaccine , ; Any condition specifically list among exclusion criterion . Subjects know prior illness risk H5N1 Influenza A virus infection , i.e . exposure two week prior study Day 0 person know H5N1 Influenza virus infection travel 2 week prior Day 0 course study region know current case H5N1 Influenza virus infection ; Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( i.e . infection disease ) illness must enrol study ; Any condition judge investigator would limit evaluation subject .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>H5N1</keyword>
	<keyword>Avian Influenza</keyword>
	<keyword>DNA Vaccine</keyword>
	<keyword>Electroporation</keyword>
	<keyword>Intramuscular ( IM ) Injection</keyword>
</DOC>